Should I buy or sell Akili stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Akili in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AKLI shares. View AKLI analyst ratings or view top-rated stocks .

What is Akili's stock price target for 2024?

1 brokers have issued 12-month target prices for Akili's stock. Their AKLI share price targets range from $4.00 to $4.00. On average, they predict the company's share price to reach $4.00 in the next year. This suggests a possible upside of 1,645.2% from the stock's current price. View analysts price targets for AKLI or view top-rated stocks among Wall Street analysts .

How have AKLI shares performed in 2024?

Akili's stock was trading at $0.4871 on January 1st, 2024. Since then, AKLI stock has decreased by 52.9% and is now trading at $0.2292. View the best growth stocks for 2024 here .

Are investors shorting Akili?

Akili saw a drop in short interest in March. As of March 31st, there was short interest totaling 123,200 shares, a drop of 30.0% from the March 15th total of 176,100 shares. Based on an average daily trading volume, of 2,330,000 shares, the short-interest ratio is currently 0.1 days. Currently, 0.3% of the shares of the stock are sold short. View Akili's Short Interest .

When is Akili's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our AKLI earnings forecast .

How were Akili's earnings last quarter?

Akili, Inc. (NASDAQ:AKLI) posted its earnings results on Thursday, February, 29th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.12. The firm had revenue of $0.75 million for the quarter, compared to analyst estimates of $1.07 million. Akili had a negative net margin of 3,545.47% and a negative trailing twelve-month return on equity of 76.34%.

How do I buy shares of Akili?

Shares of AKLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:AKLI

Akili (AKLI) Stock Price, News & Analysis

→ “Forget Tesla, this is Elon’s Next Big Thing” (From InvestorPlace) (Ad)

Free AKLI Stock Alerts

$0.23

-0.03 (-11.57%)

(As of 04/15/2024 ET)

Compare

Today's Range: $0.23
▼
$0.26
50-Day Range: $0.22
▼
$0.47
52-Week Range: $0.19
▼
$1.67

Volume: 92,788 shs
Average Volume: 256,161 shs
Market Capitalization: $18.02 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.00

Get Akili alerts:

Akili MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,645.2% Upside
$4.00 Price Target
Short Interest: Healthy
0.31% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.43
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.53) to ($0.28) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.67 out of 5 stars

Medical Sector

251st out of 928 stocks

Surgical & Medical Instruments Industry

32nd out of 99 stocks

3.5

Analyst's Opinion

Consensus Rating
Akili has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Akili has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.31% of the float of Akili has been sold short.
Short Interest Ratio / Days to Cover
Akili has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Akili has recently decreased by 30.04%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Akili does not currently pay a dividend.
Dividend Growth
Akili does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AKLI.

4.1

News and Social Media Coverage

News Sentiment
Akili has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Akili this week, compared to 1 article on an average week.
Search Interest
8 people have searched for AKLI on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.
MarketBeat Follows
2 people have added Akili to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Akili insiders have not sold or bought any company stock.
Percentage Held by Insiders
10.10% of the stock of Akili is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
53.12% of the stock of Akili is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Akili are expected to grow in the coming year, from ($0.53) to ($0.28) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Akili is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Akili is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Akili has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

>>Check out what this A.I. Perfect Storm is<<

About Akili Stock (NASDAQ:AKLI)

Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. The company was founded in 2011 and is headquartered in Boston, Massachusetts.

AKLI Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AKLI Stock News Headlines

March 11, 2024 | bizjournals.com

Digital medicine maker Akili slashed executive pay in 2023

March 3, 2024 | finance.yahoo.com

Akili Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

April 16, 2024 | InvestorPlace (Ad)

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

March 1, 2024 | markets.businessinsider.com

Akili (AKLI) Gets a Buy from TD Cowen

February 29, 2024 | businesswire.com

Akili Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

February 28, 2024 | benzinga.com

Preview: Akili's Earnings

February 28, 2024 | investing.com

Akili's ADHD digital therapy seeks Japan approval

February 27, 2024 | msn.com

Crude Oil Gains 1%; US New Home Sales Increase In January

April 16, 2024 | InvestorPlace (Ad)

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

February 27, 2024 | businesswire.com

PureTech Founded Entity Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx ® for Pediatric ADHD Patients in Japan

February 26, 2024 | investorplace.com

Why Is Akili (AKLI) Stock Up 110% Today?

February 26, 2024 | msn.com

Why Is Prescription Digital Medicine-Focused Akili Stock Trading Over 100% On Monday?

February 26, 2024 | seekingalpha.com

Akili's ADHD device submitted for Japanese approval, stock rallies 130%

February 26, 2024 | finance.yahoo.com

Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx® for Pediatric ADHD Patients in Japan

February 26, 2024 | businesswire.com

Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx® for Pediatric ADHD Patients in Japan

February 21, 2024 | finance.yahoo.com

Akili Announces Release Date for Fourth Quarter and Full Year 2023 Financial Results, Provides Investor Communications and Board and Corporate Governance Updates

February 21, 2024 | businesswire.com

Akili Announces Release Date for Fourth Quarter and Full Year 2023 Financial Results, Provides Investor Communications and Board and Corporate Governance Updates

January 15, 2024 | finance.yahoo.com

Akili, Inc. (AKLI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

January 8, 2024 | bbc.com

Akli Tadjer: French writer meets students in school race row

December 26, 2023 | cnet.com

What to Know About EndeavorRX, the Video Game to Treat ADHD

December 21, 2023 | finance.yahoo.com

Akili, Inc. (AKLI) Upgraded to Buy: Here's What You Should Know

December 21, 2023 | bizjournals.com

The Petri Dish: ADHD-treating videogame cleared for teens, CRISPR exec resigns

December 19, 2023 | morningstar.com

Akili Inc Ordinary Shares

December 18, 2023 | finance.yahoo.com

EndeavorRxⓇ, World’s First and Only Prescription Video Game Treatment, Secures FDA Label Expansion for Pediatric ADHD Patients Aged 13-17

November 15, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Urogen Pharma (URGN) and Akili (AKLI)

November 14, 2023 | morningstar.com

Akili Inc Ordinary Shares AKLI

November 13, 2023 | finance.yahoo.com

Akili, Inc. (NASDAQ:AKLI) Q3 2023 Earnings Call Transcript

See More Headlines

Receive AKLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akili and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/29/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/10/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:AKLI
CUSIP: N/A
CIK: 1850266
Web: www.akiliinteractive.com
Phone: 650-931-6236
Fax: N/A
Employees: 68
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $4.00
High Stock Price Target: $4.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +1,645.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.76)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-59,490,000.00
Net Margins: -3,545.47%
Pretax Margin: -3,542.31%
Return on Equity: -76.34%
Return on Assets: -56.48%

Debt

Debt-to-Equity Ratio: 0.09
Current Ratio: 6.02
Quick Ratio: 6.02

Sales & Book Value

Annual Sales: $1.68 million
Price / Sales: 10.72
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.75 per share
Price / Book: 0.31

Miscellaneous

Outstanding Shares: 78,600,000
Free Float: 70,658,000
Market Cap: $18.02 million
Optionable: Optionable
Beta: 1.99

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Dr. Walter Edward Martucci II (Age 41)
Ph.D., Co-Founder & Chairman
Comp: $759.1k
Mr. Matthew Franklin M.B.A. (Age 50)
President, CEO & Director
Comp: $639.13k
Dr. Adam Gazzaley M.D. (Age 54)
Ph.D., Co-Founder, Chief Science Advisor & Director
Comp: $126.45k
Ms. Jacqueline L. Studer J.D. (Age 65)
Chief Legal Officer, General Counsel & Secretary
Comp: $559.55k
Ms. Caty Reid
VP of Marketing & Communications
Dr. Scott H. Kollins Ph.D.
Chief Medical Officer
Mr. Jonathan David (Age 46)
Chief Product Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AKLI Stock Analysis - Frequently Asked Questions

Should I buy or sell Akili stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Akili in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AKLI shares.
View AKLI analyst ratings or view top-rated stocks.
What is Akili's stock price target for 2024?: 1 brokers have issued 12-month target prices for Akili's stock. Their AKLI share price targets range from $4.00 to $4.00. On average, they predict the company's share price to reach $4.00 in the next year. This suggests a possible upside of 1,645.2% from the stock's current price.
View analysts price targets for AKLI or view top-rated stocks among Wall Street analysts.
How have AKLI shares performed in 2024?: Akili's stock was trading at $0.4871 on January 1st, 2024. Since then, AKLI stock has decreased by 52.9% and is now trading at $0.2292.
View the best growth stocks for 2024 here.
Are investors shorting Akili?: Akili saw a drop in short interest in March. As of March 31st, there was short interest totaling 123,200 shares, a drop of 30.0% from the March 15th total of 176,100 shares. Based on an average daily trading volume, of 2,330,000 shares, the short-interest ratio is currently 0.1 days. Currently, 0.3% of the shares of the stock are sold short.
View Akili's Short Interest.

When is Akili's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our AKLI earnings forecast.
How were Akili's earnings last quarter?: Akili, Inc. (NASDAQ:AKLI) posted its earnings results on Thursday, February, 29th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.12. The firm had revenue of $0.75 million for the quarter, compared to analyst estimates of $1.07 million. Akili had a negative net margin of 3,545.47% and a negative trailing twelve-month return on equity of 76.34%.
How do I buy shares of Akili?: Shares of AKLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AKLI) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Akili (AKLI) Stock Price, News & Analysis

Akili MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Akili Stock (NASDAQ:AKLI)

AKLI Stock Price History

AKLI Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

AKLI Stock Analysis - Frequently Asked Questions

Overall MarketRank^™